
Biocon's Pebrilzo gets EU nod for HER2-positive breast cancer treatment
The story in brief
Biocon's Pebrilzo received EU approval for treating HER2-positive breast cancer across multiple stages, becoming the first biosimilar under EMA's tailored clinical approach. The decision followed a positive CHMP opinion on September 17, 2026, marking a key regulatory milestone for the company.